i-Démo 5 grant (France 2030) · Biotech
One Biosciences receives €3.3m France 2030 grant
The non-dilutive i-Démo 5 award supports a triple-negative breast-cancer diagnostic developed with Institut Curie.
The award will accelerate development of the company’s first single-cell diagnostic for triple-negative breast cancer.
The project applies OneMap’s single-cell tumor profiling to a defined diagnostic application. It is in development, distinct from the broader platform’s existing clinical-validation work.
Use of funds
Accelerate development of a single-cell diagnostic for triple-negative breast cancer
Funding history
i-Démo 5 grant (France 2030) · This round€3.3M